GNSZ News Alert Genspera Inc (GNSZ) 0.7600 09/29/2014 03:14:

New Post Public Reply Private Reply Replies (0) Message Board

Sep 29, 2014 at 4:14 AM

Genspera Inc (GNSZ) 0.7600 $GNSZ

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)

Genspera Wins Summary Judgment in Mhaka Litigation
PR Newswire - Thu Sep 18, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

GenSpera Receives Patent on Prodrug Targeted for Prostate Cancer
PR Newswire - Tue Sep 09, 7:20AM CDT
GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company's presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.

Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)

GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization
PR Newswire - Wed Sep 03, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association.

GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids
PR Newswire - Thu Aug 28, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids.

GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Thu Aug 14, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer
PR Newswire - Wed Jul 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available
PR Newswire - Tue Jul 22, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and investors.

Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).

GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
PR Newswire - Tue Jul 15, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5th Asia-Pacific Primary Liver Cancer Expert Meeting Saturday, July 12th, in Taipei, Taiwan.

Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
PR Newswire - Mon Jul 14, 8:20AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.

GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei
PR Newswire - Mon Jul 07, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13th in Taipei, Taiwan.

Media Advisory: GenSpera 2014 BIO International Presentation Available
PR Newswire - Mon Jun 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.

Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)

GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
PR Newswire - Tue Jun 24, 3:27PM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"
PR Newswire - Mon Jun 23, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Suunto Unleashes High-Tech Race 3S Watch with AI Coach

The Latest in Performance Gear: Suunto's Race 3S Nobody wants their gear to be a limitation, especially out in the wild where every step counts. Enter Suunto's Race 3S—a watch that looks to change the game for those passionate about trail running. This gadget's packed with features meant for athletes who are serious about their tech, yet light enough to make you forget...

Dairy Blends Market Eyes USD 15.38B by 2035 Growth

The dairy blends market, set to barrel towards USD 15.38 billion by 2035 according to Credence Research, isn't just a numbers game. It's a tug-of-war between different fats, regions, and regulations. For those betting on future market movements, this shouldn't be a passing glance. Rising from USD 9.97 billion in 2025, these figures suggest consistent waves rather than...

Winter Prep: Home Safety Vital for Older Adults

Cold Weather is All About Precaution It ain't the first day at the fair when you realize winter's sneaking up, and with it, the looming concern of older family members hunkering down indoors. Executive Home Care's calling out, saying it straight: if you've got seniors in your midst, now's the time to batten down the hatches. The winter months can turn into a slippery...

Selling Montana Cabins: Tips from Shawna Norry

Understanding the Challenges of Selling Montana Cabins When folks think about selling real estate, the logistics of marketing quaint Montana cabins or lifestyle properties can be different than your typical city apartment. In the wide-open spaces of places like Libby, Montana, seller needs aren't just about showing a property—it's about telling a story. Shawna Norry, an...

Trive Cashes Out on EarthLink, New Era with Family Offices

EarthLink's Changing Hands: What's the Real Deal? I tell you, the tech industry's like a game of hot potato, and right now, EarthLink's the spud getting tossed around. Trive Capital, the private equity force from Dallas, just wrapped up handing EarthLink over to a family office squad. That's WaveDivision Capital, The Pritzker Organization, and Stephens Capital Partners...

M&T Bank Declares Quarterly Preferred Dividends

No Surprises Here—M&T Pays Out Big On Preferreds If there's one thing the market just loves to see amid all this noise and chatter, it's cash coming back to shareholders. M&T Bank Corporation, a seasoned player in the financial sector, is keeping its shareholders happy with some neat quarterly preferred stock dividends. Now, if you've been poking around the NYSE:MTB...

Lincoln's Legal Tangle: Stock Plunge Sparks Lawsuit

Lincoln Educational's Troubles Unravel You think you've seen it all, then boom—Lincoln Educational Services hit the skids with their stock diving close to 25% back in August 2026. This ain't your usual small hiccup; we’re talking a lawsuit filed and investors eyeing action as miserly as a broker when the market tumbles. News like this? It shakes the rafters of any...

Cecilia Vicuña's Bold Exhibition at MOCA Tackles Water Crisis

Art and ecological awareness dance together on a tightrope at the Museum of Contemporary Art (MOCA) in Los Angeles. Cecilia Vicuña’s new exhibition, The Dream of Water: Quipu of Encounters Maricunga, arrives with a punch, not merely as art but as a call to arms for water conservation and environmental justice. The show kicks off on November 15, 2026, and remains open...

Digital Maps Revolutionize Navigation at UK Hospitals

Technology Making Strides in Patient Navigation You ever get lost in one of those labyrinthine hospitals? It's a nightmare, isn't it? Well, it seems St George's and Epsom hospitals have taken a step forward with a solution—MazeMap. The idea is simple: digital wayfinding. Patients and visitors have a digital map at their fingertips, helping them hop through the maze of...

WuXi Biologics Clinches Top ESG Honors in Award Circuit

Pounding the ESG Pavement Every now and then, a story pops up that makes you wonder if the finance folks are finally waking up to what's been slap-you-in-the-face obvious: sustainability ain't just a fancy word for do-gooders anymore. It's the real ticket to the future, and WuXi Biologics (2269.HK) just snagged the top-honor Jade Award at The Asset Corporate...